# Genetically Modified Mouse Core

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2021 · $169,050

## Abstract

PROJECT SUMMARY (GENETICALLY MODIFIED MOUSE CORE) 
The significant incidence of digestive, liver and pancreatic diseases in the American population demands 
continued exploration of a broad array of corresponding mechanistic pathways, pathophysiologic sequelae, 
and potential therapeutic approaches. In many cases these investigations can only be accomplished, or can 
be accomplished most efficiently and relevantly, using model systems established in intact animals. The use 
of mouse models in these pursuits is now well established for their power, feasibility, flexibility, and enormous 
potential. Creation of such models, by targeted alterations of the mouse genome, is an essential component of 
an overall research effort in understanding normal functions and pathologic perturbations in the digestive tract, 
liver, and pancreas. The Genetically Modified Mouse Core (GMMC) provides investigators of the University of 
Pennsylvania Center for the Molecular Study of Digestive and Liver Diseases (CMSDLD) with the ability to 
carry out these technologically-demanding studies in a cost effective and efficient manner and enhance the 
rigor and relevance of these approaches. The GMMC has a dedicated and highly skilled staff that applies 
state-of-the-art equipment and techniques, and the facility consists of a microinjection suite, an adjacent 
dedicated cage room, and an off-site and highly secure cryopreservation storage facility. Major services 
available to CMSDLD investigators include the generation of transgenic mice by DNA pronuclear injection, 
creation of chimeric mice by ES cell injection into blastocysts, and direct genome mutation, editing, and 
modification via the use of targeted endonuclease (TALEN and Crispr-CAS technologies); these are 
complemented by the genotyping of founder mice, assisted (in vitro) fertilization, cryopreservation, long-term 
cryostorage, and shipping of frozen embryos or sperm to/from other facilities. To provide these services, the 
GMMC utilizes multiple microinjection platforms, laser-assisted technologies, state-of-the-art cryopreservation 
approaches, and highly efficient line re-derivation pipelines. All functions, from ordering services, to following 
workflow, to storing and sending out lines, are on-line and can be monitored in real-time. These efforts by the 
GMMC contribute substantially to the overall productivity of CMSDLD investigators and enhance the rigor and 
relevance of their studies to the mechanisms of digestive, liver, and pancreatic diseases in physiologically- 
intact mammalian systems. Moreover, the GMMC enhances interactions and collaborations for CMSDLD 
investigators and lowers the technical and financial barriers that would otherwise impede the application of 
these approaches for individual investigators. Thus the Genetically Modified Mouse Core contributes greatly to 
the research efforts of the CMSDLD.

## Key facts

- **NIH application ID:** 10200773
- **Project number:** 5P30DK050306-25
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** DOUGLAS J EPSTEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $169,050
- **Award type:** 5
- **Project period:** 2020-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10200773

## Citation

> US National Institutes of Health, RePORTER application 10200773, Genetically Modified Mouse Core (5P30DK050306-25). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10200773. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*